Press release
August 18, 2026
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics N.V. (IMTX)
Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally